Physicians and Physicist Added to Expert Proton Therapy Staff

The UF Health Proton Therapy Institute welcomes two physicians and a physicist to its medical team.

 

Adam L. Holtzman, M.D.

Adam L. Holtzman, M.D.Dr. Holtzman is an assistant professor in the Department of Radiation Oncology at the University of Florida College of Medicine. While skilled in all external beam radiation modalities, he specializes in proton therapy for skull-based and central nervous system malignancies. He received his undergraduate, medical, and residency training from the University of Florida. An established researcher, his work has been published in multiple peer-reviewed medical journals and presented at international conferences. Dr. Holtzman has received multiple awards in recognition for his dedication to clinical care, compassion and research. He was honored as Best of American Society for Radiation Oncology 57th Annual Meeting, inducted into the Gold Humanism Honors Society, and received the Outstanding Resident Educator Award.

 

Raymond B. Mailhot, M.D., M.P.H.

Raymond B. Mailhot, M.D., M.P.H.Dr. Mailhot is an assistant professor in the Department of Radiation Oncology at the University of Florida College of Medicine. His areas of treatment and research include proton therapy for pediatric cancer and breast cancer. He completed his undergraduate and medical training at Washington University in St. Louis and post graduate training at Harvard University and New York University, where he served as chief resident. He has published multiple research articles in peer-reviewed medical journals and presented research at international medical conferences. His academic and professional honors include the J. Max Rukes Full Tuition Merit Scholarship, Washington University School of Medicine; Merit Scholarship, Harvard School of Public Health; Jonathan Mann Foreign Rotation Fellowship Award; and American Society of Clinical Oncology Conquer Cancer Fellowship Award. He serves on committee for the American Society for Radiation Oncology.

 

Mark Artz, Ph.D.

Mark Artz, Ph.D.Dr. Artz is an assistant professor in the Department of Radiation Oncology at the University of Florida College of Medicine. He received his bachelor’s and master’s degrees from the Massachusetts Institute of Technology, where he contributed to the development of superconducting cyclotrons and gantries for proton therapy. Most recently, as an adjunct professor at the University of Tennessee and medical physicist fellow at the Provision Proton Therapy Center, Knoxville, Dr. Artz was responsible for clinical commissioning and operation of IBA and ProNova Proton and Eleckta Photon, including treatment planning, quality assurance and clinical development. He also developed a CAMPEP Master of Science degree program in Medical Physics with the University of Tennessee College of Engineering.

 

About This Newsletter

The Precision Newsletter is an electronic-only publication that is distributed by email. Each issue is sent monthly to patients, alumni patients and friends of the University of Florida Health Proton Therapy Institute. As the official newsletter of the Institute, the content is compiled and prepared by our communications representative and approved by the editor Stuart Klein, executive director of UF Health Proton Therapy Institute. Special bulletin newsletters may occasionally be prepared when timely topics and new developments in proton therapy occur. If you would like to send a Letter to the Editor, please click here.

 

Keep In Touch

It is easy to stay in touch with us online at floridaproton.org . Look at the top right corner of the homepage for Facebook , Twitter and YouTube icons, click and join us in the social media conversation. Also on the right side of the homepage there is a button for VTOC Patient Portal . Click here to open your secure account, view your records, complete clinical trial questionnaires and communicate with your nurse case manager.

 

Knowing how you are feeling during and after treatment is essential to providing you the best care possible and contributes to the care of future patients.